Abstract:

Objective To explore the application effect of bevacizumab combined with chemotherapy in targeted therapy for colorectal cancer. Method A retrospective analysis was conducted on the clinical data of 68 patients with colorectal cancer admitted to Guangzhou Baiyunshan Hospital from June 2022 to June 2023. They were divided into a control group (chemotherapy, 33 cases) and a study group (bevacizumab+chemotherapy, 35 cases) based on diff erent treatment plans. The therapeutic effi cacy, tumor marker levels, and incidence of adverse reactions were compared between the two groups of patients. Result The disease control rate of the study group patients was 94.29%, higher than that of the control group (72.73%), with a significant difference (P ＜ 0.05). Before treatment, there was no signifi cant diff erence in the levels of carbohydrate antigen (CA) 19-9, CA 72-4, and carcinoembryonic antigen between the two groups (P ＞ 0.05); After treatment, the average levels of CA 19-9, CA 72-4, and carcinoembryonic antigen in the study group were signifi cantly lower than those in the control group (P ＜ 0.05). There was no signifi cant diff erence in the total incidence of adverse reactions between the two groups of patients (P ＞ 0.05). Conclusion Bevacizumab combined with chemotherapy can signifi cantly improve the disease control rate of colorectal cancer patients, reduce the level of tumor markers in the body, and there is no increase in the risk of adverse reactions.

Key words: Colorectal cancer, Targeted therapy, Bevacizumab, Chemotherapy, Tumor markers, Adverse reactions